中國Patent Term ExtensionPharmaUpdates and Changes
2020年4月23日

China Provides Specific Directions to Strengthen Patent / Technology Protection from 2020 to 2021

China continues to progress towards its major goal of significantly strengthening IP protection within its borders. Last year it announced several proposed amendments to its patent laws. In January 2020 China and the US signed the Economic and Trade Agreement between the Government of China and US (published 16 January 2020 –“Trade Agreement”), which detailed several areas in which China agreed to reform its laws, including in the areas of trade secrets and confidential information, pharmaceutical-related IP, piracy and counterfeiting, and enforcement.

Just a few days ago on April 20th, 2020, the Chinese National Intellectual Property Administration (CNIPA) published a long and comprehensive plan (“Plan”) on how to strengthen the protection of intellectual property in areas such as patents, trade secrets, trademarks, copyrights and plant varieties. Although many of the improvements in this Plan overlap with or are consistent with those outlined in the Trade Agreement, this new Plan is also much more comprehensive and really signals China’s overall commitment to overhauling and rapidly improving its IP system from multiple angles.

The Plan include several items that are of particular interest to technology companies with patent portfolios and trade secret concerns. Life science companies will be pleased to see patent term extension as well as stronger pharmaceutical patents and enforcement mechanisms. Counterfeits are another major concern, and the list below also devotes a significant portion to that area.

Below we have selected and summarized certain parts of the Plan that we think are more relevant and important to technology companies. The dates in parentheses indicate the target completion date for rolling out the new laws.

Reviewing and revising Chinese Patent Law including

a.    Introducing a punitive compensation system for infringement;

b.    Providing patent term extension;

c.     Strengthening protection of pharmaceutical patents;

d.    Further revising the patent examination guidelines; and

e.    Reducing the invention patent examination cycle to less than 20 months (Dec 2021)

Formulating Supreme People's Court's interpretation on:

a.    Judicial procedures for trade secret disputes (Aug 2020)

b.    Administrative cases concerning patent authorization and confirmation (Aug 2020)

c.     Criminal cases of intellectual property infringement (Aug 2020)

d.    Enforcement of online infringement and counterfeiting (Aug 2020)

Enhancing IP Enforcement by:

a.    Considering the evidence rules related to intellectual property such as certification of legal documents and witness testimony (Oct 2020)

b.    Establishing an early resolution mechanism for pharmaceutical patent disputes (Oct 2020)

c.     Reviewing regulations on infringement of trade secrets (Oct 2020)

d.    Studying and establishing a system of technical investigators for administrative protection of intellectual property rights. Continue to improve the working mechanism of using technical investigators in the Courts (Dec 2021)

e.    Separating IP cases of different natures and different degrees of complexity into different streams to expedite court proceedings

Improving Systems and Policies Surrounding Counterfeits

a.    Formulating policies for the destruction of infringing and counterfeit goods (Jul 2020)

b.    Fighting against counterfeit goods with health and safety risks with increased frequency and establish a system for publicly releasing the above-mentioned law enforcement action data and information on a quarterly basis (May 2020)

c.     Cracking down on counterfeit medicines and biological products and other related products. Strengthen international cooperation in law enforcement with relevant countries

d.    Establishing a system for publicly releasing data on the enforcement of counterfeit drugs on an annual basis (Jul 2020)

e.    Establishing a system for publicly releasing information on law enforcement actions related to intellectual property in the country on a quarterly basis (May 2020)

f.     Look into the setting up of industry departments with the authority to delete website containing infringing links, close infringing or counterfeit web accounts (Dec 2021)

Improving Systems and Policies Surrounding Infringement Disputes / Evidence Collection

a.    Developing a pilot scheme for the inspection and identification of patent and trademark infringement disputes and infringement damage assessment system

b.    Strengthening intellectual property arbitration and mediation organizations

c.     Researching and formulating guidelines on notarization in evidence collection of intellectual property infringement including how to apply technology for electronic notarization, third-party notarization and verification of notarization data (Dec 2021)

d.    Supporting the establishment of a notary electronic deposit service alliance, and explore the application of block chain and other scientific and technological means in the promotion of notary electronic deposit technology

Developing Policies Around Trade Secrets

a.    Developing policies to strengthen the protection of business secrets and confidential business information during the administrative licensing process (Oct 2020)

Traditional Chinese Medicine

a.    Promoting/revising regulations on the protection of traditional knowledge of Chinese medicine

It is certainly and aggressive list with aggressive timelines for completion. We await and see how such vast changes can be implemented in the coming 1-2 years. We will continue to keep a close eye on current updates in China’s patent law landscape and will keep you updated on the latest interesting patent law news.

Related Posts

Major and Exciting Changes to China's Patent Law (Draft 4th Amendment)
Finally, A Unified "Court of Appeal" for Technology IP in China
AI, Big Data, and Blockchain - CNIPA Seeks Public Comment on Draft Examination Guidelines

About the Authors

Dr. Jacqueline Liu, is President and Founder of Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

Jennifer Che, J.D. is Vice President and Principal at Eagle IP, a Boutique Patent Firm with offices in Hong Kong, Shenzhen, and Macau.

[email protected]

This article is for general informational purposes only and should not be considered legal advice or a legal opinion on a specific set of facts.

其他文章

China Hands Down First Batch of Patent Linkage “Paragraph IV” Litigation Results

2022年6月30日
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage. Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]

2020 China Top 10 IP Cases: Winners’ Sun is truly a Winner: A Simple Selfie-Stick Utility Model Patent Crushes Infringers in China

2021年8月2日
Each year The Intellectual Property Tribunal of the Supreme People’s Court releases a list of top 10 technical intellectual property rights court case decisions. The 2020 list came out a few months ago, and we have been highlighting some of these cases. Today, we will cover a utility model patent infringement case. As one of […]

AI is magical but NOT magic! Be specific in your AI patents!

2025年1月9日
What is the standard of sufficient disclosure for AI-related patents: A case study in China The rapid growth of AI patent applications present significant challenges to existing patent application and examination practices. One of them is satisfying the requirement for sufficient disclosure. The following case was featured in the 2023 CNIPA Compilation of Key Decisions […]
Tapentadol.svg

Polymorph Patents in China: What is the Standard for Inventiveness for New Crystal Forms?

2020年7月14日
This case is focused on polymorphs, namely what are the standards for novelty and inventiveness when it comes to new crystal forms of a known drug? A recent Supreme People’s Court decision in China is illustrative of the way Chinese courts are thinking about polymorph patents in China. Grünenthal is a German pharmaceutical company and […]

我們過去活動

Top crossarrow-right